Robert S. Weinstein, M.D ., Paula K. Roberson, Ph.D., and Stavros C. Manolagas, M.D., Ph.D.: Giant Osteoclast Development and Long-Term Oral Bisphosphonate Therapy Bisphosphonates are used worldwide to prevent fractures in patients with osteoporosis.1-6 Treatment with these drugs decreases the price of bone resorption and degrees of biochemical markers of bone turnover and causes progressive boosts in bone mineral density. The scientific efficacy of nitrogen-comprising bisphosphonates is widely thought to result from their potent capability to decrease the number of osteoclasts by promoting their apoptosis.7-9 Once osteoclasts become apoptotic, they are usually quickly ingested by bone marrow phagocytes.10 However, enumeration of osteoclasts in specimens of cancellous bone acquired from individuals treated with nitrogen-containing bisphosphonates displays surprisingly little, if any, change in the amount of osteoclasts.11,12 This observation shows that the mechanism by which these drugs work in vivo varies from the current thinking.

Comparisons had been performed regarding to randomized treatment assignments. Univariate comparisons were performed with the use of the chi-square test for discrete variables and the Wilcoxon rank-sum test for continuous variables. P ideals are reported without adjustment for multiple comparisons. We also calculated 95 percent confidence intervals for outcomes at each time stage in the PCI group as compared with the medical-therapy group on the basis of the t distribution. Results Research Population Of the 2166 patients enrolled in OAT, 1970 were enrolled by the final end of 2004, and 951 of these patients were enrolled in the quality-of-life substudy .